Cancer Chemotherapy: Basic Science to the Clinic / Edition 1

Cancer Chemotherapy: Basic Science to the Clinic / Edition 1

by Rachel Airley
ISBN-10:
0470092548
ISBN-13:
9780470092545
Pub. Date:
05/26/2009
Publisher:
Wiley

Hardcover

Current price is , Original price is $187.95. You
Select a Purchase Option
  • purchase options

Overview

Cancer Chemotherapy: Basic Science to the Clinic / Edition 1

This textbook is a clear and accessible introduction to thescientific and clinical aspects of the creation, development andadministration of drugs or drug regimens used in the treatment ofcancer. Unique in its approach, this book enables the student togain an understanding of the pathological, physiological andmolecular processes governing malignancy, whilst also introducingthe role of health professionals and scientists in the research andtreatment of cancer. The book consolidates all the essentialinformation necessary for a full understanding of cancerchemotherapy, providing an informative, inexpensive and up-to-datecoverage of the subject aimed at an undergraduate level readership.

Key Features:

  • Incorporates numerous diagrams, tables and illustrations to aidunderstanding.
  • Examines key pharmacological and pharmaceutical issues such asdosing, toxicity and preparation of anti-cancer drugs.
  • Includes a key chapter of practice essay questions to easerevision.
  • Comprehensive coverage of drugs currently in pre-clinical andclinical development.
  • An indispensable text for undergraduate students studyingpharmacy and medicine as well as those doing courses such asmolecular biology, biomedical sciences and pharmacology which coveraspects of oncology.

Product Details

ISBN-13: 9780470092545
Publisher: Wiley
Publication date: 05/26/2009
Pages: 342
Product dimensions: 6.80(w) x 9.80(h) x 1.00(d)

Read an Excerpt

Click to read or download

Table of Contents

Preface ix

1 Cancer epidemiology 1

1.1 Cancer incidence, prevalence and mortality 1

1.2 Childhood cancers 3

1.3 Global epidemiology 6

2 Histopathology of cancer 11

2.1 Introduction 11

2.2 Malignant, benign and normal (non-malignant) tissue 11

2.3 Cell death 12

3 Carcinogenesis, malignant transformation and progression 19

3.1 Introduction 19

3.2 Chemical carcinogenesis 19

4 Molecular biology of cancer: oncogenes and tumour suppressor genes 23

4.1 Introduction 23

4.2 Oncogenesis 25

4.3 Tumour suppressor genes 30

5 Tumour metastasis: a convergence of many theories 37

5.1 Introduction 37

5.2 Detachment and migration from the primary tumour 37

5.3 Intravasation 38

5.4 Transport 42

5.5 Extravasation 43

5.6 Growth of the metastatic tumour mass 45

6 Health professionals in the treatment of cancer 49

6.1 Introduction 49

6.2 Pathology 49

6.3 Radiology 50

6.4 Role of the surgical oncologist 51

6.5 Oncology pharmacy 52

6.6 Oncology nursing 53

6.7 The NHS Cancer Plan 54

7 Principles of cancer chemotherapy 55

7.1 Introduction 55

7.2 Timing of chemotherapy 55

7.3 Biomarkers and their uses 59

7.4 Clinical assessment of biomarkers 59

7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 64

8 Classical anticancer agents 67

8.1 Introduction 67

8.2 Alkylating agents 67

8.3 Antimetabolites 71

8.4 Agents derived from natural or semisynthetic products 77

8.5 Hormonal anticancer agents 106

8.6 Clinically used chemotherapy regimens 111

9 The philosophy of cancer research 117

9.1 Introduction 117

9.2 Structure of cancer research organizations in the United Kingdom 118

9.3 Cancer research in the United States 120

10 Novel anticancer agents 125

10.1 Introduction 125

10.2 Target validation 125

10.3 Identification and optimization of lead drugs 146

10.4 Preclinical pharmacology 148

11 Clinical trials 167

11.1 Introduction 167

11.2 Evaluation of treatment response 169

11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology 173

12 Tumour hypoxia 177

12.1 Introduction 177

12.2 Bioreductive drugs 181

12.3 Inhibitors of HIF-1 and HIF-1-regulated genes 187

13 Antiangiogenic and antivascular agents 199

13.1 History of angiogenesis as a therapeutic target 199

13.2 Anti-angiogenic drug targets 202

13.3 The return of thalidomide 209

13.4 Monoclonal antibodies as anti-angiogenic agents 212

13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs 213

13.6 Vascular disrupting agents 215

14 Tyrosine kinase inhibitors 217

14.1 Introduction 217

14.2 Tyrosine kinase inhibitors targeting angiogenesis 219

14.3 Non-receptor tyrosine kinase inhibitors 221

15 Ras inhibitors 225

16 Inhibitors of the Akt/PKB pathway 229

17 Targeting stress proteins: HSP90 inhibitors 233

18 The proteasome 237

18.1 Introduction 237

18.2 The proteasome as a target for novel drug strategies 239

18.3 Ubiquitylation as a target 240

19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR) 245

19.1 Mammalian target of rapamycin 245

19.2 Structure and activation of mTOR 246

19.3 Novel anticancer agents targeting mTOR 248

20 Telomerase 249

21 Histone deacetylase: an epigenetic drug target 255

21.1 Introduction 255

21.2 HDAC and DNA packaging 255

21.3 HDAC inhibitors 261

22 Pharmaceutical problems in cancer chemotherapy 265

22.1 Manifestation of toxicity 265

22.2 Regimen-related toxicity 269

22.3 Secondary malignancies 270

22.4 Drug resistance 271

22.5 Pharmaceutical complications 274

22.6 Phlebitis and venous irritation 279

22.7 Health and safety 279

22.8 National guidance on the safe administration of intrathecal chemotherapy 279

23 Oncology pharmacy at home and abroad 281

24 Practice exam questions 283

25 Bibliography and further reading 299

Index 331

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews